Laryngeal Neuroendocrine Neoplasms: Analysis of 11 Cases in a Single-Center Study

Abstract

Objective: Laryngeal neuroendocrine neoplasms (LNEN) are rare, and there have been previous uncertainties regarding their classification and treatment modalities. This article aims to share our treatment experience, elucidate changes in LNEN classification, and discuss the treatment implications of different types and stages. Methods: A retrospective analysis was conducted on 11 cases of LNEN treated through surgical intervention at the Department of Otolaryngology, Qilu Hospital of Shandong University, Qingdao, from January 2014 to November 2023. Among the 11 cases, there were 9 males and 2 females, with ages ranging from 61 to 77 years. Pathological classifications included neuroendocrine tumors (NET) G1 (1 case), G2 (2 cases), G3 (5 cases), small-cell neuroendocrine carcinoma (2 cases), and large-cell neuroendocrine carcinoma (1 case). The follow-up period ranged from 1 to 115 months. Results: Treatment modalities varied among the cases: 5 patients underwent transoral laser microsurgery (TLM) without neck dissection, 1 patient underwent TLM with unilateral neck lymph node dissection, 1 patient underwent open partial supraglottic laryngectomy (OPSL) with ipsilateral neck lymph node dissection, and 4 patients underwent OPSL with bilateral neck lymph node dissection. Among the 11 patients, 4 died, with 2 succumbing to distant metastasis, 1 to local recurrence, and 1 to other diseases. Conclusion: The prognosis of LNEN is closely associated with the latest pathological classification and TNM staging. For a more detailed and specific clinical staging, further research involving multicenter large-scale data is needed.

Keywords

neuroendocrine pathological classification larynx surgery endoscopy prognosis

Introduction

Neuroendocrine tumors (NETs) are a rare type of tumor that originates from neuroendocrine cells, which are characterized by their ability to synthesize and secrete neuropeptides and hormones as well as the expression of neuroendocrine markers such as synaptophysin and chromogranin.¹ These tumors can occur at any location but are commonly found in the lungs, pancreas, rectum, appendix, and small intestine. On the other hand, laryngeal neuroendocrine neoplasms (LNEN) are even rarer, accounting for less than 1% of all laryngeal tumors,² and primarily manifest in the supraglottic region (57.9%-95.5%).³ Symptoms in affected individuals vary based on the location and size of the tumor, with common local manifestations including discomfort in the pharynx and larynx, hoarseness, and swallowing difficulties. In addition to complications arising from the space-occupying effects of the tumor, attention should also be directed toward complications resulting from the endocrine functions of NETs, such as paraneoplastic syndromes. While paraneoplastic syndromes are less common in LNEN compared to NETs occurring in other locations, there have been reported cases.⁴ Risk factors for LNEN include smoking, human papillomavirus (HPV) infection, among others.^3,5,6 As understanding of LNEN deepens, its classification has evolved, leading to occasional challenges for clinicians during certain periods.⁷ The evolution of classification is shown in Table 1.The most recent classification standard is the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms, which aligns with the classification for gastrointestinal NETs.^8,9 From the perspective of the evolution of NETs classification, there is a gradual trend toward unification in the classification of all NETs, including those of the digestive and respiratory systems.

Table 1.

Classifications of Laryngeal Neuroendocrine Neoplasms.

Gould¹⁰	Woodruff et al¹¹	Wenig et al¹²	WHO¹³	WHO¹⁴	WHO¹⁵	WHO⁹
Very well differentiated neuroendocrine carcinoma	Typical carcinoid	Well-differentiated neuroendocrine carcinoma	Typical carcinoid	Typical carcinoid	Well differentiated	Well-differentiated neuroendocrine neoplasm (NET)	NET, G1 NET, G2 NET, G3
Well-differentiated neuroendocrine carcinoma	Large-cell neuroendocrine carcinoma	Moderately differentiated neuroendocrine carcinoma	Atypical carcinoid	Atypical carcinoid	Moderately differentiated	Well-differentiated neuroendocrine neoplasm (NET)	NET, G1 NET, G2 NET, G3
Intermediated/poorly differentiated neuroendocrine carcinoma	Small-cell neuroendocrine carcinoma	Poorly differentiated neuroendocrine carcinoma	Small cell Intermediate cell Large cell	Small cell	Poorly differentiated Small cell Large cell	Poorly differentiated neuroendocrine neoplasm (Neuroendocrine carcinoma)	Small cell Neuroendocrine carcinoma Large cell neuroendocrine carcinoma
				Combined small cell and non-small cell

Abbreviations: NET, Neuroendocrine tumor; WHO, World Health Organization.

Methods

This study is a single-center investigation, where all patients underwent surgical treatment, and the authors were directly involved in patient care. The surgeries were collectively performed as a treatment group. On admission, comprehensive laboratory tests, contrast-enhanced computed tomography scan of the neck and chest, neck ultrasound, electronic laryngoscopy with narrow-band imaging, pathological biopsies, and other examinations were conducted to assess the primary tumor, neck lymph nodes involvement, and the presence of distant metastasis. Following a multidisciplinary team discussion (MDT), individualized treatment plans were formulated based on TNM staging and the patient’s specific condition. If the primary tumor could be completely excised orally, transoral laser microsurgery (TLM) was performed. In cases where the tumor was too large for complete oral excision, open partial supraglottic laryngectomy (OPSL) was undertaken based on the tumor characteristics. For cases with cTxN1~3M0, neck lymph node dissection was carried out. If cT1N0M0, observation or ipsilateral neck lymph node dissection was considered. Postoperatively, additional radiotherapy and chemotherapy were administered based on the tumor’s classification and TNM staging at the time, following a treatment regimen similar to that for laryngeal squamous cell carcinoma (LSCC). In November 2023, after a reexamination of pathological slides by head and neck surgical pathologists according to the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms, the patients were reclassified. Patient demographics, smoking index, P16 expression, preoperative biopsies, pathological classification at the time of surgery, current pathological classification, Ki67/mitoses, surgical methods, and prognosis were recorded and analyzed using SPSS 26 for Kaplan-Meier survival analysis. The basic characteristics and prognosis of the 11 patients are summarized in Table 2. The pathological classification and prognosis of 11 patients were illustrated using a Swimmer plot, as shown in Figure 1.

Table 2.

Characteristics of Patients, Tumors, and Treatment.

Patient No.	Sex/age (y)	Tumor site	Smoking Pack-Yeas index	P16	Histologic diagnosis (Initial)	Histologic diagnosis (2022 WHO)	Biopsy	Ki67/mitoses	Surgical approach	TNM	Prognosis and cause of death	Survival time (months)
1	F/72	Epiglottis	0	−	G2	NET, G2	No	10%/2	TLM	T1N0M0	Living	115
2	M/61	Epiglottis	30	+	Well-differentiated neuroendocrine carcinoma (G2)	NET, G2	Yes(G2)	15%/3	TLM	T1N0M0	Death	57
3	M/66	Epiglottis	10	+	LCNEC	LCNEC	Yes (poorly differentiated squamous-cell carcinoma)	40%/10	OPSL + BLND	T1N2cMx	Death (distant metastasis)	32
4	F/77	AEF	7.5	absence	Well-differentiated NET	NET, G1	Yes (NEN)	Absence	TLM	T1N0M0	Death (21 mo local recurrence;60 mo death)	60
5	M/61	Epiglottis	40	+	Atypical carcinoid	NET, G3	No (suspected hemangioma)	30%/2	TLM	T1N0M0	Living	57
6	M/65	Epiglottis	60	+	LCNEC	NET, G3	No	40%/8~9	OPSL + BLND	T2N2cM0	Death	16
7	M/75	AEF	25	+	Moderately differentiated neuroendocrine carcinoma	NET, G3	Yes (NEN, typical carcinoid)	25~30%/2	TLM	T1N0M0	Living	19
8	M/69	AEF	10	−	NET, G3	NET, G3	No	25%/8	TLM + ILND	T1N2bM0	Living	10
9	M/68	Epiglottis	50	+	NET, G3	NET, G3	No	40%/6	OPSL + BLND	T2N2cM0	Living (7 mo cervical lymph node recurrence)	10
10	M/67	Epiglottis	153	+	SCNEC	SCNEC	Yes (poorly differentiated carcinoma, tend to SCC)	90%/43	OPSL + BLND	T1N1M0	Living	2
11	M/76	Ventricular bands	50	+	SCNEC	SCNEC	Yes (SCC)	95%/85	OPSL + ILND	T1N1M0	Living	1

Abbreviations: AEF, aryepiglottic fold; BLND, bilateral neck dissection; F, female; ILNC, ipsilateral neck dissection; LCNEC, large-cell neuroendocrine carcinoma; M, male; ND, neck dissection; NEN, neuroendocrine neoplasm; NET, neuroendocrine tumor; OPSL, open partial supraglottic laryngectomy; SCC, squamous cell carcinoma; SCNEC, small-cell neuroendocrine carcinoma; TLM, transoral laser microsurgery.

Figure1.

Swimmer plot. Time 0 represents the date of surgery, axis represents survival time (months), Y-axis represents patient No.

Results

The follow-up period ranged from 1 to 115 months. Among the cases, there were 8 NETs, with 5 surviving and 3 deceased. One patient died due to local recurrence (discovered 21 months postoperatively, and succumbed 60 months after surgery), another due to the underlying condition, and 1 due to distant metastasis. There were also 3 NEC cases, including 1 large-cell neuroendocrine carcinoma (LCNEC; deceased due to distant metastasis) and 2 small-cell neuroendocrine carcinomas (SCNECs). The Kaplan-Meier survival curve is depicted in Figure 1. All 11 tumors originated in the supraglottic region, with 7 originating in the epiglottis, 3 in the aryepiglottic fold (AEF), and 1 in the ventricular band region. Surgical approaches included TLM in 6 cases and OPSL in 5 cases. Preoperatively, 6 cases underwent pathological biopsy, with 3 accurate reports and 3 diagnosed as squamous cell carcinoma (SCC). Among the 11 patients, 10 were smokers, with 7 being heavy smokers. P16 was tested in 10 patients, with 8 testing positive (80% positivity rate).

In terms of pathological classification and prognosis:

NET G1: 1 case, originating from the right AEF, T1N0M0, treated with TLM. Local recurrence was discovered at the 21st month of follow-up, and due to the patient’s advanced age and other personal reasons, surgery was foregone. The patient succumbed to in situ recurrence at the 60th month after surgery, with no evidence of neck lymph node or distant metastasis during follow-up (Figure 2).

NET G2: 2 cases, both originating from the epiglottis, T1N0M0. One case survived 115 months postoperatively, and the other died due to the underlying condition. Both cases were treated with TLM, with no additional radiotherapy or chemotherapy postoperatively.

NET G3: 5 cases, 2 originating from the anterior epiglottic fold and 3 from the epiglottis. Among them, 2 were T1N0M0, 2 were T2N2cM0, and 1 was T1N2bM0. One case died 16 months postoperatively due to distant metastasis, while another case had neck lymph node recurrence discovered 7 months postoperatively and is currently undergoing radiotherapy. Surgical approaches included TLM in 2 cases, TLM with ipsilateral neck lymph node dissection in 1 case, and OPSL with bilateral neck lymph node dissection in 2 cases.

SCNEC: 2 cases, with 1 originating from the tongue side of the epiglottis and initially diagnosed as SCC. Surgical approach was OPSL with bilateral neck lymph node dissection, and postoperative pathology confirmed combined SCC and SCNEC (approximately 80% SCNEC, 20% SCC), Ki67 90%, mitoses 43/2 mm². The other case originated from the left ventricular band region and was preoperatively considered as SCC. Surgical approach was OPSL with ipsilateral neck lymph node dissection, and postoperative pathology confirmed SCNEC, Ki67 95%, mitoses 85/2 mm². Both cases were staged as pT1N1M0.

LCNEC: 1 case, originating from the epiglottis. Preoperative biopsy at an external institution suggested poorly differentiated SCC. The surgical approach was OPSL with bilateral neck lymph node dissection, staged as pT1N2cM0. Six months postoperatively, an abdominal mass was discovered but left untreated. Twenty-three months postoperatively, enlarged neck lymph nodes were found, and at the 25th month postoperatively, neck lymph node dissection plus removal of the abdominal mass was performed. Postoperative pathology confirmed LCNEC metastasis to neck lymph nodes and the abdominal wall. The patient succumbed 32 months after the initial surgery.

Kaplan-Meier survival analysis for the 11 cases is presented in Figure 3, with an overall 5 year survival rate (OS) of 25.7%.

Figure 2.

Survival curve of 11 patients with LNEN. LNEN, laryngeal neuroendocrine neoplasms.

Figure 3.

The laryngoscope of NET G1. (A) presurgery, originating from the right aryepiglottic fold; (B) 2 months after surgery; (C) 11 months after surgery; (D) 21 months after surgery, local recurrence; (E and F) 47 months after surgery, local recurrence is more pronounced. NET, neuroendocrine tumor.

Discussion

Within the head and neck region, the larynx emerges as the predominant site for neuroendocrine carcinoma (NEC). Despite constituting less than 1% of all laryngeal tumors, laryngeal NEC (LNEC) stands out as the most prevalent nonsquamous subtype.¹⁶ The supraglottis, particularly the AEF, demonstrates a strong predilection, accounting for 82% of cases Bal et al’s study.¹⁷ In our research, 64% (7/11) originated from the epiglottis, while 27% (3/11) originated from the AEF. The survival rate of NEC occurring in the larynx is higher compared to that arising in other locations, albeit lower than the survival rate of LSCC.² Risk factors for LNEC include smoking and HPV infection, with the majority of patients having a history of tobacco use (73.3%-94.2%).³ The respiratory systems of the larynx and lungs, both exposed to similar tobacco and environmental stimuli, see a higher prevalence of small-cell lung cancer among pulmonary NETs. Rekhtman reported an association between small-cell lung cancer and smoking, and with declining smoking rates, a decrease in small-cell lung cancer incidence was observed, while non-small-cell lung cancer rates increased.⁸ In our study, patients with SCNEC were heavy smokers and exhibited P16 positivity. However, laryngeal NETs predominantly manifest as atypical carcinoids, necessitating further clarification of associated risk factors. During electronic laryngoscopy, some NETs may resemble vascular lesions, requiring careful differentiation. Among our cases with preoperative pathological biopsy results, there were 2 misdiagnoses, yielding a misdiagnosis rate of 40%. This underscores the importance of preoperative biopsies in diagnosing LNEC, emphasizing the need for experienced practitioners to obtain samples and skilled pathologists for accurate pathological diagnosis.

NETs originate from neuroendocrine cells (peptidergic neurons), and in the larynx, these cells are scattered within the mucosal epithelium. Laryngeal NETs are classified into 2 major categories based on their tissue origin: epithelial and neurogenic.¹⁸ Prior to the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms, epithelial laryngeal NETs were mainly classified as carcinoid tumors, atypical carcinoids, etc.¹⁹ However, various diagnostic terms have been applied to what is now recognized as neuroendocrine tumor/NET (a well-differentiated epithelial NEN) and NEC (a poorly differentiated epithelial NEN; Table 1). The classification of these NETs of the larynx has been a subject of considerable debate over the years, primarily revolving around terminology and classification systems. Various systems have been proposed, with some advocating for consistency with classification systems for neuroendocrine neoplasms in other organ systems (lung and gastrointestinal), while others propose unique systems for the head and neck.²⁰ The lack of uniform standards, coupled with confusion in classification and a limited number of cases, has impeded in-depth research on laryngeal NEC. As a result, diagnostic standards and treatment approaches often borrow from those established for NETs in the lungs and gastrointestinal tract.

More recently, a unified IARC/WHO terminology framework for all neuroendocrine neoplasms, irrespective of their site of origin, has been proposed.^21,22 The 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms (see Table 1) categorizes tumors based on differentiation into NET and NEC. NETs are further stratified into G1, G2, and G3 based on the presence of cellular necrosis, mitotic figures, and Ki-67 index. NECs are classified into SCNEC and LCNEC. The criteria for mitotic figures are set at 50 per high-power field, with Ki-67 expression assessed in the strongest staining area, counting 500 to 2000 tumor cells, and recalculating. In cases where mitotic figures and Ki-67 indices do not align, a higher grade is recommended.²³ Immunohistochemical stains for several antibodies (INSM1, synaptophysin, chromogranin A) can aid in confirming neuroendocrine differentiation based on appropriate morphology.²⁴

In our center’s study involving NETs with accompanying neck lymph node metastasis, we employed a method that separately counts the primary tumor and lymph nodes. This classification method provides clear counting criteria, transforming empirical practices into measurable objective data. It has standardized diagnostic criteria, reduced human errors, and facilitated the collection, exchange, and statistical analysis of multicenter cases. However, this classification lacks targeted research on laryngeal NEC’s ability to differentiate between different tumor biological behaviors and prognoses, necessitating large-scale case studies and time validation.

The treatment outcomes are strongly influenced by the histological subtype of laryngeal NEC, with a 5 year disease-specific survival of 100% for typical carcinoid tumors, 52.8% for atypical carcinoid tumors, 19.3% for SCNEC, and 15.3% for LCNEC.³ In our study, the overall 5 year survival rate was 25.7%. However, the limitations of a small sample size and a relatively short follow-up duration introduce potential errors into the results.

The therapeutic options and prognosis vary significantly based on the pathological types and TNM staging of laryngeal NEC. Combining our 11 cases with existing literature, NET G1 exhibits a relatively benign biological behavior, characterized by slow tumor growth and a low tendency for lymph node metastasis. The preferred treatment approach involves surgical resection, ideally employing transoral laser surgery, which often yields favorable outcomes.^2,25 For NET G2, concurrent neck lymph node dissection is recommended during surgical resection, even in the absence of radiological evidence of lymph node metastasis. This precaution is due to early-stage lymph node metastasis that may go undetected by imaging studies. NET G3, when treated with partial laryngeal resection, has shown effective control of the primary tumor. However, it is often associated with lymph node metastasis, especially when double-neck lymph node involvement is present, leading to a poorer prognosis. The postoperative debate revolves around whether to combine surgery with radiotherapy or chemotherapy.

SCNEC and LCNEC exhibit lower survival rates, but they can benefit from chemotherapy.^3,26 The treatment approach should be personalized, considering the TNM staging and involving MDTs.²⁷ Immunotherapy is still in the early stages of clinical exploration. Horn et al’s report suggests that immune checkpoint inhibitors have demonstrated efficacy in treating extensive-stage small cell lung cancer when combined with etoposide and platinum, replacing chemotherapy alone as the standard first-line treatment.²⁸ In summary, a comprehensive treatment strategy, including surgery, radiotherapy, chemotherapy, and immunotherapy, should be tailored based on the tumor subtype and TNM staging.

The 2022 WHO classification has provided a clear classification standard for head and neck NET, categorizing them into NET G1, G2, G3, SCNEC, and LCNEC. The prognosis of laryngeal NETs is closely associated with pathological subtyping and TNM staging. However, given the rarity of LNEN, further analysis with larger datasets, following a standardized pathological classification, is essential to establish a robust foundation for treatment planning.

Conclusions

LNEN exhibit a poorer prognosis. Beyond traditional approaches involving surgery, radiotherapy, and chemotherapy, novel therapeutic modalities are imperative to enhance survival rates. The prognosis of laryngeal NETs is closely associated with the latest pathological classification and TNM staging. For a more detailed and specific clinical staging, further research involving multicenter large-scale data is needed.

Supplemental Material

sj-png-1-ear-10.1177_01455613241249270 – Supplemental material for Laryngeal Neuroendocrine Neoplasms: Analysis of 11 Cases in a Single-Center Study

Supplemental material, sj-png-1-ear-10.1177_01455613241249270 for Laryngeal Neuroendocrine Neoplasms: Analysis of 11 Cases in a Single-Center Study by Jianlin Yue, Qianqian Zhao, Suyuan Sun, Xinliang Pan and Dayu Liu in Ear, Nose & Throat Journal

Supplemental Material

sj-png-2-ear-10.1177_01455613241249270 – Supplemental material for Laryngeal Neuroendocrine Neoplasms: Analysis of 11 Cases in a Single-Center Study

Supplemental material, sj-png-2-ear-10.1177_01455613241249270 for Laryngeal Neuroendocrine Neoplasms: Analysis of 11 Cases in a Single-Center Study by Jianlin Yue, Qianqian Zhao, Suyuan Sun, Xinliang Pan and Dayu Liu in Ear, Nose & Throat Journal

Footnotes

Author Contributions

All authors were involved in the conception. JY wrote the first draft, which was reviewed and revised by XP and DL. QZ provided the pathological content in this article. SS is responsible for patient follow-up. All authors have read and approved the final version of the manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical Approval

Not applicable.

ORCID iD

Jianlin Yue

Supplemental Material

Supplemental material for this article is available online.

References

Fang

Shi

. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. WJG. 2022;28:1009-1023.

Wang

Liu

She

. Clinical diagnosis and treatment of primary laryngeal neuroendocrine carcinoma. Ear Nose Throat J. 2023:1-6.

Van Der Laan

Plaat

BEC

Van Der Laan

BFAM

Halmos

. Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: a meta-analysis of 436 reported cases: neuroendocrine carcinoma of the larynx. Head Neck. 2015;37:707-715.

Ferlito

Rinaldo

Bishop

, et al. Paraneoplastic syndromes in patients with laryngeal neuroendocrine carcinomas: clinical manifestations and prognostic significance. Eur Arch Otorhinolaryngol. 2016;273:533-536.

Halmos

Van Der Laan

Van Hemel

, et al. Is human papillomavirus involved in laryngeal neuroendocrine carcinoma? Eur Arch Otorhinolaryngol. 2013;270:719-725.

Zefan

Lei

. Research advances in neuroendocrine carcinoma of the larynx. J Otolaryngol Ophthalmol Shandong Univ. 2022;36:114-119.

La Rosa

Uccella

. Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord. 2021;22:527-538.

Rekhtman

. Lung neuroendocrine neoplasms: recent progress and persistent challenges. Modern Pathol. 2022;35:36-50.

Mete

Wenig

. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms. Head Neck Pathol. 2022;16:123-142.

10.

Gould

. Neuroendocrine tumors in ‘“miscellaneous”’ primary sites: clinical, pathologic, and histogenetic implications. Progr Surg Pathol IV. 1982;IV:181-198.

11.

Woodruff

Huvos

Erlandson

, et al. Neuroendocrine carcinomas of the larynx: a study of two types, one of which mimics thyroid medullary carcinoma. Am J Surg Pathol. 1985;9:771-790.

12.

Wenig

Hyams

Heffner

. Moderately differentiated neuroendocrine carcinoma of the larynx: a clinicopathologic study of 54 cases. Cancer. 1988;62:2658-2676.

13.

El-Mofty

. World Health Organization International Classification of Tumours: Histological Typing of Tumors of the Upper Respiratory Tract and Ear, Second Edition. Am J Clin Pathol. 1992;98:464-465.

14.

Thompson

LDR

. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J. 2006;85:74.

15.

El-Naggar

Chan

JKC

Grandis

, et al. WHO Classification of Head and Neck Tumours. 4th ed. IARC; 2017:9.

16.

Ghosh

Dutta

Dubal

Park

Baredes

Eloy

. Laryngeal neuroendocrine carcinoma: a population-based analysis of incidence and survival. Otolaryngol Head Neck Surg. 2015;153:966-972.

17.

Bal

Sharma

Rane

, et al. Neuroendocrine neoplasms of the larynx: a clinicopathologic analysis of 27 neuroendocrine tumors and neuroendocrine carcinomas. Head Neck Pathol. 2022;16:375-387.

18.

Ferlito

Silver

Bradford

Rinaldo

. Neuroendocrine neoplasms of the larynx: an overview. Head Neck. 2009;31:1634-1646.

19.

Ferlito

Lewis

Rinaldo

. The evolving management of laryngeal neuroendocrine carcinomas. Eur Arch Otorhinolaryngol. 2011;268:1247-1248.

20.

Hunt

Ferlito

Hellquist

, et al. Differential diagnosis in neuroendocrine neoplasms of the larynx. Adv Anat Pathol. 2017;24:161-168.

21.

Rindi

Inzani

. Neuroendocrine neoplasm update: toward universal nomenclature. Endocrine-Related Cancer. 2020;27:R211-R218.

22.

Rindi

Klimstra

Abedi-Ardekani

, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathol. 2018;31:1770-1786.

23.

Bosman

Carneiro

Hruban

, et al. WHO Classification of Tumours of the Digestive System. 4th ed, Vol. 3. World Health Organization; 2010:p.417.

24.

Rindi

Mete

Uccella

Basturk

, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33:115-154.

25.

López

Hunt

Nixon

, et al. How phenotype guides management of the neuroendocrine carcinomas of the larynx. J Laryngol Otol. 2018;132:568-574.

26.

Bacalao

Beg

Cavuoti

, et al. Head and neck neuroendocrine tumors at a single institution over 15 years. Clin Case Rep. 2019;7:2508-2512.

27.

Sousa

Lazar Neto

Torman

, et al. Therapeutic approaches and outcomes in patients with larynx or hypopharynx high-grade neuroendocrine carcinoma: a single-center retrospective analysis. Head Neck. 2021;43:3788-3795.

28.

Horn

Mansfield

Szczęsna

, et al. First-Line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.09 MB

0.20 MB